Cargando…
Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors
mTOR pathway activation and hypervascularity have been identified as important characteristics of pancreatic neuroendocrine tumors (pNETs). Agents targeting angiogenesis and mTOR, such as sunitinib and everolimus (RAD001), have been shown to result in progression-free survival of approximately 11 mo...
Autores principales: | Chu, Pei-Yi, Jiang, Shih Sheng, Shan, Yan-Shen, Hung, Wen-Chun, Chen, Ming-Huang, Lin, Hui-You, Chen, Yu-Lin, Tsai, Hui-Jen, Chen, Li-Tzong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732754/ https://www.ncbi.nlm.nih.gov/pubmed/29262588 http://dx.doi.org/10.18632/oncotarget.21665 |
Ejemplares similares
-
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
por: Alonso-Gordoa, Teresa, et al.
Publicado: (2015) -
Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters
por: Ingenerf, Maria, et al.
Publicado: (2022) -
Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know
por: de Ponthaud, Charles, et al.
Publicado: (2021) -
Mitochondrial phosphoenolpyruvate carboxykinase promotes tumor growth in estrogen receptor‐positive breast cancer via regulation of the mTOR pathway
por: Hsu, Hui‐Ping, et al.
Publicado: (2022) -
Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing’s syndrome: treatment response with chemotherapy
por: Rajeev, Surya Panicker, et al.
Publicado: (2014)